Contraindicated in:
Use Cautiously in:
CNS: NEUROLEPTIC MALIGNANT SYNDROME, confusion, disorientation, sedation, dizziness, extrapyramidal reactions, fatigue, insomnia, nervousness.
EENT: blurred vision, diplopia, tinnitus.
CV: bradycardia, hypertension, hypotension, tachycardia.
GI: constipation, drug-induced hepatitis, dry mouth.
Derm: photosensitivity, severe tissue necrosis upon infiltration at IV site, rashes.
Hemat: blood dyscrasias.
Drug-Drug:
(Generic available)
Antihistamine
2 yr): 0.1 mg/kg/dose (not to exceed 12.5 mg) q 6 hr during the day and 0.5 mg/kg/dose (not to exceed 25 mg) at bedtime.
2 yr): 0.125 mg/kg q 46 hr or 0.5 mg/kg at bedtime.Antivertigo (Motion Sickness)
2 yr): 0.5 mg/kg (not to exceed 25 mg) 3060 min before departure; may be given q 12 hr as needed.Sedation
Sedation during Labor
Antiemetic
2 yr): 0.251 mg/kg (not to exceed 25 mg) q 46 hr.Therapeutic Classification: antiemetics, antihistamines, sedative/hypnotics
Pharmacologic Classification: phenothiazines
Absorption: Well absorbed after oral (88%) and IM administration; rectal administration may be less reliable.
Distribution: Widely distributed; crosses the blood-brain barrier and the placenta.
Protein Binding: 6590%.
Metabolism/Excretion: Metabolized by the liver.
Half-life: 916 hr.
(noted as antihistaminic effects; sedative effects last 28 hr)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO, IM | 20 min | unknown | 412 hr |
| Rectal | 20 min | unknown | 412 hr |
| IV | 35 min | unknown | 412 hr |
NDC Code*